173 related articles for article (PubMed ID: 36871936)
1. A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
Wang X; Wang Y; Gou S
Int J Biochem Cell Biol; 2023 Apr; 157():106395. PubMed ID: 36871936
[TBL] [Abstract][Full Text] [Related]
2. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
Wang Y; Wang X; Xu G; Gou S
J Med Chem; 2021 Apr; 64(7):4163-4178. PubMed ID: 33784109
[TBL] [Abstract][Full Text] [Related]
3. HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
Lombardi R; Sonego M; Pucci B; Addi L; Iannelli F; Capone F; Alfano L; Roca MS; Milone MR; Moccia T; Costa A; Di Gennaro E; Bruzzese F; Baldassarre G; Budillon A
Mol Oncol; 2021 Apr; 15(4):1005-1023. PubMed ID: 33331136
[TBL] [Abstract][Full Text] [Related]
4. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
5. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways.
Huang L; Zhao L; Zhang J; He F; Wang H; Liu Q; Shi D; Ni N; Wagstaff W; Chen C; Reid RR; Haydon RC; Luu HH; Shen L; He TC; Tang L
Aging (Albany NY); 2021 Jul; 13(13):17407-17427. PubMed ID: 34232919
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
7. Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
Wang Y; Luo Z; Zhou D; Wang X; Chen J; Gong S; Yu Z
Biomater Sci; 2021 Jun; 9(11):4110-4119. PubMed ID: 33949442
[TBL] [Abstract][Full Text] [Related]
8. Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin.
Guo WJ; Zhang YM; Zhang L; Huang B; Tao FF; Chen W; Guo ZJ; Xu Q; Sun Y
Autophagy; 2013 Jul; 9(7):996-1008. PubMed ID: 23580233
[TBL] [Abstract][Full Text] [Related]
9. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
[TBL] [Abstract][Full Text] [Related]
10. FOXO3a Reverses the Cisplatin Resistance in Ovarian Cancer.
Lu M; Chen X; Xiao J; Xiang J; Yang L; Chen D
Arch Med Res; 2018 Feb; 49(2):84-88. PubMed ID: 29716743
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.
Tummala R; Diegelman P; Fiuza SM; Batista de Carvalho LA; Marques MP; Kramer DL; Clark K; Vujcic S; Porter CW; Pendyala L
Oncol Rep; 2010 Jul; 24(1):15-24. PubMed ID: 20514439
[TBL] [Abstract][Full Text] [Related]
12. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
13. Design of a novel Pt(II) complex to reverse cisplatin-induced resistance in lung cancer
Jiang M; Yang T; Chu Y; Zhang Z; Sun H; Liang H; Yang F
Dalton Trans; 2022 Mar; 51(13):5257-5270. PubMed ID: 35285843
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Kulshrestha A; Katara GK; Ginter J; Pamarthy S; Ibrahim SA; Jaiswal MK; Sandulescu C; Periakaruppan R; Dolan J; Gilman-Sachs A; Beaman KD
Mol Oncol; 2016 Jun; 10(6):789-805. PubMed ID: 26899534
[TBL] [Abstract][Full Text] [Related]
15. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
[TBL] [Abstract][Full Text] [Related]
16. Mithplatins: Mithramycin SA-Pt(II) Complex Conjugates for the Treatment of Platinum-Resistant Ovarian Cancers.
Bhosale SS; Mandal A; Hou C; McCorkle JR; Schweer D; Hill KS; Subramanian V; Kolesar JM; Tsodikov OV; Rohr J
ChemMedChem; 2023 Feb; 18(3):e202200368. PubMed ID: 36342449
[TBL] [Abstract][Full Text] [Related]
17. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
18. Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.
Lin M; Wang X; Zhu J; Fan D; Zhang Y; Zhang J; Guo Z
Apoptosis; 2011 Mar; 16(3):288-300. PubMed ID: 21107699
[TBL] [Abstract][Full Text] [Related]
19. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
[TBL] [Abstract][Full Text] [Related]
20. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]